Trial Profile
A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Ciclosporin; Corticosteroids; Corticosteroids; Etretinate; Methotrexate
- Indications Pustular psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 23 Mar 2018 Results published in the Media Release
- 23 Mar 2018 According to an AbbVie media release, based on the results of this trial the company has received additional approval for a new indication of HUMIRA in the treatment of patients who have had an inadequate response to conventional therapy for pustular psoriasis.
- 21 Jul 2017 Status changed from active, no longer recruiting to completed.